Success Bio-Tech Co., Ltd. is mainly engaged in the R&D, production and sales of biomedical devices for implant intervention. Relying on a mature scientific research team and adhering to independent innovation, the company has broken through and mastered a number of key core technologies and production processes. It has leading technologies in the field of biomaterials such as hemostasis and surgical anti adhesion, tissue sealing and protection, interventional embolization, tissue engineering, etc. some products have achieved "domestic initiative", and it is a domestic leading enterprise in subdivided industries.

Represented by Composite Microporous Polysaccharide Hemostatic Powder and Gel for Prevention of Postsurgical Adhesions, the company has strong technological leadership and scientific research advantages in the field of hemostasis and surgical anti adhesion. The company's Composite Microporous Polysaccharide Hemostatic Powder has been widely used in trauma surgery in the fields of surgery, gynecology and obstetrics, orthopedics, Urology, burn department and so on. This product generates "instant gel" by absorbing water through hydrophilic molecular sieve, mechanically plugging vascular breaks, stimulating and strengthening endogenous coagulation mechanism, and shortening coagulation time. It is the only composite starch absorbable hemostatic product in China, with a strong scientific research level; Another product, The Gel for Prevention of Postsurgical Adhesions , was identified as a "national key new product". As an industry model of The Gel for Prevention of Postsurgical Adhesions, the company was invited by the China food and Drug Control Institute to participate in the formulation of national standards for chitosan products.

In the field of tissue sealing and protective biomaterials, the company successfully developed Absorbable Dural Sealant and Absorbable Vascular Sealant in 2018 and 2019.Both of them are the first in China, with high technical threshold and broad clinical application prospects. Among them,Absorbable Dural Sealant is the first product that has passed the "special approval for innovative medical devices"National Medical Products Adminstration, was listed in the "catalogue of innovative medical devices" by the Ministry of Science and Technology, and was rated as "China's good technology" by the China Productivity Promotion Center Association in 2019;Absorbable Vascular Sealant was rated as the "science and technology development plan project" of Jinan High Tech Zone and the "science and technology plan project of Shandong Province" of Shandong Provincial Department of science and technology.

In the field of interventional embolization biomaterials.The non-adhesive liquid embolization materials is the first non-adhesive liquid embolic material used for BAVM treatment in China, and it is still the only domestic brand in this field. The company has a strong technological leadership in the field of interventional embolization. The successful listing of this product fills the domestic gap, not only meets the domestic demand, but also reduces the economic burden of patients, and makes a positive contribution to promoting the development of interventional embolization in China.

In the field of tissue engineering biomaterials, the company has deployed tissue engineering products under development, such as biological amniotic chorion and biological amniotic corneal repair materials. Among them, biological amniotic chorion has the advantages of good biocompatibility and water permeability, and has excellent effect in promoting wound healing. At present, the project has entered the clinical evaluation stage, and there is no similar product with the same indication in China.
In the next stage, the company will based on the fields of hemostasis and surgical anti-adhesion, tissue sealing and protection, interventional embolization, and tissue engineering biomaterials, and continue to explore the application of the company's core technology in new fields and new indications of interventional biomaterials, so as to build a three excellent enterprise with technology representation, technology innovation, and technology leadership in the industry. Meanwhile, the company continued to explore domestic blank fields with clinical needs, relying on its own core technology reserves and scientific research strength, to achieve domestic replacement of key medical devices, in order to promote the rapid development of the company while improving national living standards and medical quality, and seek development opportunities with the country.

Represented by Composite Microporous Polysaccharide Hemostatic Powder and Gel for Prevention of Postsurgical Adhesions, the company has strong technological leadership and scientific research advantages in the field of hemostasis and surgical anti adhesion. The company's Composite Microporous Polysaccharide Hemostatic Powder has been widely used in trauma surgery in the fields of surgery, gynecology and obstetrics, orthopedics, Urology, burn department and so on. This product generates "instant gel" by absorbing water through hydrophilic molecular sieve, mechanically plugging vascular breaks, stimulating and strengthening endogenous coagulation mechanism, and shortening coagulation time. It is the only composite starch absorbable hemostatic product in China, with a strong scientific research level; Another product, surgical anti adhesion fluid, was identified as a "national key new product". As an industry model of surgical anti adhesion liquid products, the company was invited by the China food and Drug Control Institute to participate in the formulation of national standards for chitosan products.

In the field of tissue sealing and protective biomaterials, the company successfully developed absorbable dural sealing medical glue and absorbable vascular sealing medical glue in 2018 and 2019. These medical devices are the first in China, with high technical threshold and broad clinical application prospects. Among them, the absorbable dural sealing medical adhesive is the first product that has passed the "special approval for innovative medical devices" of the State Food and drug administration, was listed in the "catalogue of innovative medical devices" by the Ministry of science and technology, and was rated as "China's good technology" by the China Productivity Promotion Center Association in 2019; The absorbable vascular sealing medical adhesive product was rated as the "science and technology development plan project" of Jinan high tech Zone and the "science and technology plan project of Shandong Province" of Shandong Provincial Department of science and technology.

In the field of interventional embolization biomaterials, the company's non adhesive liquid embolic agent product is the first non adhesive liquid embolic material used for BAVM treatment in China, and it is still the only domestic brand in this field. The company has a strong technological leadership in the field of interventional embolization. The successful listing of this product fills the domestic gap, not only meets the domestic demand, but also reduces the economic burden of patients, and makes a positive contribution to promoting the development of interventional embolization in China.

In the field of tissue engineering biomaterials, the company has deployed tissue engineering products under development, such as biological amniotic chorion and biological amniotic corneal repair materials. Among them, biological amniotic chorion has the advantages of good biocompatibility and water permeability, and has excellent effect in promoting wound healing. At present, the project has entered the clinical evaluation stage, and there is no similar product with the same indication in China.

In the next stage, the company will base itself on the fields of hemostasis and surgical anti adhesion, tissue sealing and protection, interventional embolization, and tissue engineering biomaterials, and continue to explore the application of the company's core technology in new fields and new indications of interventional biomaterials, so as to build a three excellent enterprise with technology representation, technology innovation, and technology leadership in the industry. At the same time, the company continued to explore domestic blank fields with clinical needs, relying on its own core technology reserves and scientific research strength, to achieve domestic replacement of key medical devices, in order to promote the rapid development of the company while improving national living standards and medical quality, and seek development opportunities with the country.